The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021 – GlobeNewswire
- NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors – BioSpace
- Biogen looks to build better gene therapies through latest deal – BioPharma Dive
- From one genomic diagnosis, researchers discover other treatable health conditions – National Human Genome Research Institute
- Gene and Cell Therapy Breakthroughs Focus of World Medical – GlobeNewswire
- vagina innie outie comparison
- jackson avery and aprils child
- jackson and aprils daughters name
- the numbness not going away after teeth extraction
- innie vs outie labia
- greys anatomy ortiz
- dr ortiz greys anatomy
- jaw numbnesd after a tooth extraction
- greys anatomy cast dr ortiz
- mother daughter interna on greys amatomy
|Search Immortality Topics:|
Category Archives: Longevity
Global Longevity and Anti-senescence Therapy Market Trends and Forecast interpreted by a new report – WhaTech
Global Longevity and Anti-senescence Therapy Market Trends and Forecast
The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.
The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023.
The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies,.
Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.
The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.
Get Exclusive PDF Sample Copy of This Report:www.trendsmarketresearch.com/report/sample/11698
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.
- 71 data tables and 40 additional tables- An overview of the global longevity and anti-senescence therapy market- Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023- Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa- Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process- Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics- A look at the clinical trials and expected launch of anti-senescence products- Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology
Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography.
Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.
Get a full access overview AccessNow:www.trendsmarketresearch.com/checkou698/Single
Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.
An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).
According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED.
An increasing geriatric population across the globe will generate huge growth prospectus to the market.
Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics,.
are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies,. These factors are poised to drive market growth over the forecast period.
Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.
Grab Your Report! Please click here:www.trendsmarketresearch.com/report/ount/11698
The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others.
Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED.
Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics.
For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.
For more information:
Last year, Vice-President of the United States Kamala Harris introduced a bill to the United States Senate that aimed to fund both research and education on uterine fibroids. With an estimated 26 million Americans experiencing fibroids, and about 20 percent to 80 percent of women set to developfibroidsby the time they reach age 50 worldwide, its important that we follow VP Harris path and raise awareness about this debilitating condition.
Fibroids are noncancerous tumors (less than one in 1000 can turn cancerous) that grow in the uterus. They are made of muscle and other tissues. Their size can range from pea-sized to as big as a tennis ball, and sometimes even larger. Some women may even have multiple fibroids.
Some women with fibroids dont experience any symptoms. However, others may experience debilitating symptoms, as well as fertility problems and pregnancy complications. Whats more, various research has found that fibroids disproportionately affect women of color.
According to Johns Hopkins Medicine, nine out of 10 women will develop fibroids before theyre 50 years old, and in relation to white women, the statistics are even more frightening.
According to research, black women:
There are a few risk factors that can increase ones risk of developing fibroids.
According to a Chinese study published in theAsia Pacific Clinical NutritionSociety, being overweight or obese can increase ones risk for uterine fibroids.
Statistics have revealed that;
Data published in the International Journal of Womens Health suggested that low vitamin D levels can increase the likelihood of developing fibroids.
That said, research has found that vitamin D deficiencies are more prevalent in the black community (1). This may be because high levels of melanin hinder the production ofvitamin Din the skin.
Hair relaxers are products used to help straighten black womens hair. The politics of black hair aside, research has found that these products may deteriorate a black womens health.
A 2012 study published in the American Journal of Epidemiology examined over 23 000 African-American women over a period of 12 years. The researchers found that women who use hair relaxers are 1.17 times more likely to develop fibroids, and women who use hair relaxers 7 or more times a year are 1.23 times more likely to develop fibroids.
While this study was published in 2012, more recent research has highlighted the dangers of chemical relaxers. According to a study from the National Institutes of Health, black women who use hair relaxers at least every five to eight weeks are 30% more likely to develop breast cancer.
Serena Williams revealed to VOGUE magazine that while giving birth to her child, she began to experience pulmonary embolism (blood clots that block arteries in the lungs) symptoms.
Having had a history of pulmonary embolism, Williams described her symptoms to a nurse. She asked for a CT scan and blood thinner. Unfortunately, the nurse dismissed her pleas and a doctor ordered an ultrasound for her legs instead. Following the ultrasound sound that discovered nothing, Williams received a CT scan that confirmed her suspicions.
Unfortunately, the embolism had caused Williams to cough so severely that her cesarean section wound opened. Moreover, during surgery to close the wound, doctors found a pool of blood outside the blood vessel in her abdomen. Williams then had to then undergo even more surgery to prevent additional clots from spreading. As a result, she was on bed rest for the first six weeks of motherhood.
While some may say that Williams story is a once-off unfortunate incident, a study published in the Proceedings of the National Academy of Sciences of the United States of America found that medical practitioners hold a bias towards black people and their tolerance for pain, which often causes them to ignore or disregard Black womens physical pain.
Furthermore, a study published in Epidemiology found that perceived racism was associated with an increased risk of fibroids in US-born black women.
Women with fibroids may experience the following:
In addition to the physical effects, women with fibroids have revealed that the symptoms can cause significant distress, affecting their quality of life and increasing the risk for anxiety and body image issues (2).
It also doesnt help that many women delay receiving treatment as they believe their symptoms are normal. By the time they do see a doctor, they are anemic, as well as fatigued, and very sick. This is why it is important to monitor your body for symptoms and reach out to your health practitioner. Remember: Bleeding heavily for 10 days is not normal.
While the risk for cancer is low, if left unmanaged, fibroids can lead to anemia, decreased fertility, increased pain, and they can even block your fallopian tubes (3).
For heavy bleeding and a more normal cycle, your doctor may prescribe contraceptives.
This is a medication that falls under GnRH agonists. The class of medications stimulates hormones in an effort to shrink fibroids and stop heavy bleeding.
This is a procedure whereby small particles are injected into fibroids. This is meant to shrink them and ease painful symptoms.
IUDs are meant to reduce heavy bleeding, but they do very little to address the presence of fibroids.
This is a procedure whereby a surgeon removes the fibroids from your uterus, without taking out the healthy tissue.
Women with fibroids who still want to bear children often undergo this procedure. That said, it should be noted that fibroids can still grow back after a myomectomy.
A hysterectomy remains the most effective way to remove fibroids and eliminate any chance of them growing back.
Because a hysterectomy refers to the irreversible removal of the uterus. This is a very big decision. Its important that you take your time and weigh your options before deciding to undergo a hysterectomy. Remember, once your uterus is gone, you cant put it back.
A Mediterranean diet can help you both manage and reduce your risk of developing fibroids.
Increase your intake of fresh vegetables, fruits, legumes, nuts, and seeds as well as fish.
A study published in the Current Obstetrics and Gynecology Reportsfound that women who drink one or more beers a day increase their risk for fibroids by more than 50%.
Some studies have suggested that red meat can increase levels of estrogen, which can increase your risk for fibroids. So, it may be best to monitor your red meat consumption.
As we know, green tea is incredibly rich in a number of antioxidants that can help to protect our health. It appears that one of these antioxidants may even help to protect against fibroids.
A 2013 study found that participants who had drunk green tea experienced less severe symptoms, and their fibroids shrunk in size.
Shop for green tea online.
Sugary and processed foods can increase the risk of fibroids, and they can even worsen symptoms.
Exercising has a number of benefits, and that includes reducing your risk for fibroids,
If you already have fibroids, and you want to stay active, try low-impact exercises such as walking, jogging, or swimming.
Elevated levels of estrogen can increase your risk for fibroids, or worsen symptoms.
One way to manage estrogen levels would be by avoiding endocrine disruptors. These are chemicals found all around us that can make their way into the body and disrupt hormone levels.
Additionally, some foods contain phytoestrogens. These are compounds that can mimic the estrogen found in the body, potentially causing a host of problems. Phytoestrogens can be found in soy products and red meat injected with hormones.
In addition to getting more sun (after using the appropriate sun protection products), you can also increase your vitamin D intake with supplements or by eating more egg yolks, fatty fish as well as fortified dairy products andcereals.
Its important to familiarise yourself with fibroid symptoms so that you can address the issue before it becomes problematic. While you may have been told otherwise, incredibly painful periods and heavy bleeding are not normal. You should reach out to your medical professional if you begin to experience any of the above-mentioned symptoms.
Everybody, regardless of their race, gender, and sexual orientation, deserves access to dignified care.
Dont shy away from holding your doctor accountable by asking them questions. If you feel that you are not being heard, you have the right to seek a second opinion.
Yes, black women tend to develop fibroids more often than women of other races. However, they can still manage to protect their health by managing them in the appropriate manner. Having fibroids isnt the end of the world. Many black women still go on to live happy and healthy lives despite this condition. As long as they reach out to their healthcare professional and receive the appropriate care.
Go here to read the rest:
How Can Black Women Protect Themselves Against Fibroids? - Longevity LIVE - Longevity LIVE
Ishant Sharma Was Prepared To Bowl 20 Overs A Day, That’s The Reason For His Longevity – VVS Laxman – Cricket Addictor
Former India batsman, VVS Laxman reveals that he was impressed by Ishant Sharmas will to bowl long spells when he first met the pacer. Laxman lavishes praises on the hard work the Ishant has done since making his debut in 2007 to pick 300 Test match wickets.
On Monday, in Chennai, against England with the wicket of Dan Lawrence, Ishant became the 6th Indian bowler and only the third Indian pacer after Kapil Dev and Zaheer Khan to bag 300 Test wickets.
The lanky seamer has had a career marred with injuries, however, illustrious with some scintillating spells over the years as he reached this feat in his 98th Test. It is often talked about how captains, in domestic cricket and for the national team, have a liking for Ishant because of his endurance to bowl longer spells.
When I was tweeting about his 300th wicket, I remembered the debut Test match of Ishant in 2007 against Bangladesh. A tall, lanky fast-bowler. We all knew he had the talent to do well for India. But the amount of hard work he exhibited throughout his career.
There was Zaheer and other talented fast bowlers like RP Singh, Sreesanth, or Irfan Pathan, but here was one fast bowler who was ready and prepared to bowl 20 overs every day not every innings but every day. Theres a reason why he has had this longevity, VVS Laxman told Star Sports.
VVS Laxman observed that Ishant has a better wrist position and is bowling more fuller lengths than he used to prior to the time spend with former Australia pacer, Jason Gillespie. After remaining unsold in the IPL auction, Ishant went to England to play county cricket for Sussex in 2018 where he was coached by Gillespie.
VVS Laxman reckons the senior India pacer returned a much better and improved bowler from his stint in the county. And rightly so; since the start of 2018, he has picked 74 wickets in 19 Tests at an average of 19.39; compared to the average of 36.55 in his previous 79 Tests.
What changed since 2018, is his wrist position. He is a very hard-working bowler, always looking to improve. He went to Sussex, worked with Jason Gillespie, played in the country championship, and was working on his seam position. And this is what he got right. Since then, he is pitching the ball up and he is ending up getting more wickets, Laxman added.
Also Read: Had Kuldeep Yadav Played For Some Other Country, He Would Have Taken 200 Wickets And Played 50 Tests By Now, Says His Coach Kapil Pandey
A total of 1trn of defined benefit (DB) pension longevity risk will be insured through de-risking transactions by the end of 2031, Hymans Robertson has predicted.
According it the firms 2021 Risk Transfer Report, buy-ins, buyouts and longevity swaps have insured 0.3trn of risk from DB pension schemes since 2007. This is expected to increase by 0.7trn between now and the end of 2031.
Around 180bn of the 0.3trn came through buy-ins and buyouts, while approximately 110bn was insured through longevity swaps.
Hymans Robertson estimated that around 450bn of the 0.7trn of growth up to 2031 will be driven by buy-ins and buyouts at an average of over 40bn per year.
The remainder of the increase is expected to come through longevity swaps.
Commenting on the findings, Hymans Robertson head of risk transfer, James Mullins, said: 1trn of insurance would be equivalent to around half of the value of all gilts currently issued by the UK government or around half the value of all of the companies in the FTSE 100.
Indeed, with the level of growth in pension scheme buy-ins and buyouts that we are projecting, we can expect to see several insurance companies become some of the largest companies in the FTSE 100 over the next 10 years.
Our analysis projects when each individual DB pension scheme in the UK is expected to be able to afford to insure its pension promises.These projections show that we expect demand from pension schemes for buy-ins and buyouts to average at over 40bn a year during the next decade.
This is due to a combination of factors such as funding requirements meaning that sponsoring employers will need to fund pension schemes to a higher level and the cost of insuring deferred member liabilities having reduced materially in recent years. These points mean that the additional money a pension scheme needs to get to buyout is less than it has been in the past.
This gap will reduce further as pension schemes mature, as more contributions are paid in and as investment risk is reduced further.
Mullins added that the longevity risk associated with around 17 per cent of all DB liabilities in the UK has now been insured, up from around 1 per cent 10 years ago.
During 2020, approximately 54bn of DB pension risk was transferred to insurers, with around 30bn coming form buy-ins and buyouts, and approximately 24bn from longevity swaps, making 2020 the second-highest total on record, after 2019.
Follow this link:
DB pension de-risking expected to total 1trn by 2031 - Pensions Age
Buy-ins/buy-outs and longevity swaps have insured 0.3 trillion of risk from DB pension schemes since 2007;
By the end of 2031, an additional 0.7 trillion of DB pension scheme risk is expected to have been insured;
Around 450 billion of this growth is expected to come from buy-ins and buy-outs, at an average of over 40 billion a year up to 2031, with the remainder coming from longevity swaps;
During 2020, around 55 billion of DB scheme risk was transferred to insurance companies the second highest total on record with around 30 billion of buy-ins/buy-outs and 24 billion of longevity swaps.
The analysis undertaken by the leading pensions and benefits consultancy in its report shows that since this market took off in 2007, buy-ins/buy-outs (c180bn) and longevity swaps (c110bn) have already insured 0.3 trillion of risk from DB pension schemes. Further analysis by the firm projects that by the end of 2031, an additional 0.7 trillion of defined benefit pension scheme risk is expected to have been insured as a result of significant projected growth in this market, resulting in a total of 1 trillion.
According to the report around 450 billion of this growth is expected to come from buy-ins and buy-outs, with the remainder coming from longevity swaps. During 2020, around 55 billion of defined pension scheme risk was transferred to insurance companies, with around 30 billion of buy-ins/buy-outs and 24 billion of longevity swaps. Despite the additional challenges posed by COVID-19, 2020 was the second highest total on record, only narrowly behind the record year in 2019.
Putting this analysis into context, James Mullins, head of risk transfer at Hymans Robertson, says:1 trillion of insurance would be equivalent to around half of the value of all gilts currently issued by the UK Government or around half the value of all of the companies in the FTSE 100. Indeed, with the level of growth in pension scheme buy-ins and buy-outs that we are projecting, we can expect to see several insurance companies become some of the largest companies in the FTSE 100 over the next 10 years.
Our analysis projects when each individual defined benefit pension scheme in the UK is expected to be able to afford to insure its pension promises. These projections show that we expect demand from pension schemes for buy-ins and buy-outs to average at over 40 billion a year during the next decade. This is due to a combination of factors such as funding requirements meaning that sponsoring employers will need to fund pension schemes to a higher level and the cost of insuring deferred member liabilities having reduced materially in recent years. These points mean that the additional money a pension scheme needs to get to buy-out is less than it has been in the past. This gap will reduce further as pension schemes mature, as more contributions are paid in and as investment risk is reduced further.
The UK pension scheme risk transfer market is leading the world in terms of volume, maturity and innovation, with around 0.3 trillion of pension scheme risk now having been insured via buy-ins, buy-outs and longevity swaps. To put that into context, that means that the longevity risk associated with around 17% of all defined benefit pension scheme liabilities in the UK has now been insured, up from just 1% ten years ago. Pension scheme risk transfer is developing rapidly in other countries too, such as the USA, Netherlands and Canada and those countries are watching with interest how the market develops in the UK.
Hymans Robertson 2021 Risk Transfer Report
Exercise is longevity's lifeblood because it wards off numerous chronic diseases, such as heart disease. What's more, you don't have to do much exercise to unlock the benefits. Research suggests walking every day can extend your lifespan.
Several studies have linked the mild intensity exercise to longevity but a study published in the British Medical Journal (BMJ) examined the association between time spent walking and life expectancy.
The authors followed up 27,738 participants aged 40 to 79years and prospectively collected data on their survival covering a 13-year-period.
The researchers found participants who walked one hour per day had a longer life expectancy from 40years of age than participants who walked less than onehour per day.
In addition to their longer life expectancy, participants who walked one hour per day required a lower lifetime medical expenditure from 40years of age than participants who walked less than an hour per day.
READ MORE:How to live longer: Tea with a slice of lemon could reduce cancer risk and boost longevity
In their concluding remarks, the researchers said: "Encouraging people to walk may extend life expectancy and decrease lifetime medical expenditure, especially for men."
Evidence suggests it is not only the duration of walking that counts but also the pace.
People who have a faster walking pace outlive those who walked more slowly, according to researchers who monitored the walking habits and deaths of nearly 475,000 people, most of whom were in their 50s at the start of the study.
Brisk walking was defined by researchers as walking at least three miles per hour, or 100 steps a minute.
DON'T MISSSouth Africa variant symptoms: The 15 possible signs[TIPS]Rice water for hair growth: Does it make hair grow?[ADVICE]Why Captain Moore did not take vaccine[INSIGHT]
It is worth nothing that walking pace was self-reported by participants, who were asked to indicate whether they walked at a slow pace, steady/average pace, or brisk pace.
The study, published in Mayo Clinic Proceedings, found that participants with brisk walking paces had longer life expectancies across all categories of body mass index (BMI).
BMI is a measure of body fat based on height and weight that applies to adult men and women.
The survival is the same for fast walkers for a wide range of body mass index, from 20 to 40, Dr. Francesco Zaccardi, a clinical epidemiologist at the University of Leicester in the United Kingdom and the studys lead researcher, told Healthline.
This result indicates that physical function is a stronger determinant of longevity than body mass index, and also people with high body mass index but with a good fitness may survive longer."
Conversely, participants with slower walking paces had shorter life expectancies across all categories of BMI.
Researchers reported that women who walked more quickly had a life span of about 87 years compared to 72 years for women who walked slowly.
Men who walked quickly had a life span of about 86 years compared to 65 years for men who walked more slowly.
Thats a 15-year average difference for women and a 20-year average difference for men.
Eating a healthy, balanced diet is an important part of maintaining good health, and can help you feel your best.
The Eatwell Guide shows that to have a healthy, balanced diet, people should try to:
"If you're having foods and drinks that are high in fat, salt and sugar, have these less often and in small amounts," adds the NHS.